Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
April 19, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
March 18, 2021 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

HOUSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
March 11, 2021 16:15 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
March 08, 2021 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
March 04, 2021 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
March 03, 2021 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Announces Proposed Public Offering of Common Stock

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
February 24, 2021 07:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Relapsed and refractory Ewing sarcoma patients to receive seclidemstat in combination with chemotherapy agents as second- and third-line therapy; Protocol amendment expands and improves access to...
February 22, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
February 17, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right